The ITCC-P4 PDX Platform Enables Preclinical Testing of Pediatric Cancers.
- Open access
The ITCC-P4 platform developed 353 pediatric cancer PDX models, enabling preclinical testing and biomarker discovery for high-risk solid tumors.
- Why it matters: Pediatric cancer survival is hindered by tumor heterogeneity and limited targeted therapies, creating a critical need for better preclinical models and predictive biomarkers.
- What they did: The team established and molecularly characterized a large, diverse collection of PDX models from diagnostic and relapsed pediatric tumors, including serial models for comprehensive testing.
- The result: This platform facilitates targeted therapy development and biomarker identification, supporting researchers in advancing personalized treatments for pediatric cancers.